Sangamo Therapeutics said the Food and Drug Administration has cleared its investigational new drug application for its ST-400 treatment for intractable pain due to idiopathic small fiber neuropathy.

Cardiometabolic disease biotech NeuroBo Pharmaceuticals is shaking up its corporate image with a complete rebrand. | ...

Albuquerque Acupuncture and Integrative Medicine is a local clinic specializing in treating complex chronic illnesses such as ...

Founded with a mission to address the “last-mile” challenges in pain relief, Doloromics integrates artificial intelligence ...

Envista Holdings Corporation ("Envista") today announced that the company will participate in a fireside chat at the Evercore HealthCONx Conference on Tuesday, December 3, 2024 from 12:30 ? 1:15 pm ET ...

AbbVie has announced the European Commission (EC) has granted marketing authorization for ELAHERE (mirvetuximab soravtansine) ...

Eli Lilly and Company announced today that it has elected Jon Moeller as a new member of its board of directors, effective Dec. 1, 2024. In addition, the company announced that Karen Walker will ...

GREENSBORO, N.C. — WFMY News 2 spoke about a vital issue for millions of people – managing glucose levels when you’re living ...

Intellia's Phase 3 trial for NTLA-2002 shows promise, but limitations warrant caution. See why we believe NTLA stock is hold ...

Excess cholesterol is known to form artery-clogging plaques that can lead to stroke, arterial disease, heart attack, and more, making it the focus of many heart health campaigns.

Discover Patanjali’s Madhugrit, an Ayurvedic diabetes solution blending natural herbs with scientific research to manage ...

November is Diabetes Awareness Month, with November 14th designated as World Diabetes Day to highlight the growing prevalence ...